AVBP Stock Forecast & Price Target

ArriVent BioPharma Inc is positioned well for significant stock performance owing to its promising clinical-stage development of furmonertinib, with high probabilities of success (85%) for pivotal Phase III data in 2025, as well as encouraging proof of concept results for treatment-naïve non-small cell lung cancer (NSCLC). The company has a robust potential revenue estimate of $1 billion in the US from its targeted indications, indicating substantial market opportunity, especially if additional indications and its antibody-drug conjugate pipeline succeed. Furthermore, with shares trading at a favorable market cap of approximately $740 million, the outlook suggests significant upside potential driven by key upcoming catalysts and advancements in regulatory visibility.

ArriVent BioPharma's negative outlook is underscored by a projected full-year 2025 net loss of $2.88 per share, reflecting a challenging financial trajectory. Key risks include slower enrollment and potential negative efficacy data from the Phase 3 FURVENT trial, which could impede the advancement and clinical development of its lead candidate furmonertinib and other pipeline assets. Additionally, disappointing efficacy results from the Phase I FURTHER study and the longer timeline for earlier pipeline candidates exacerbate concerns about the company's ability to deliver value in the near to medium term.